SHPG:NGS-Shire plc

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 169.89

Change

+0.94 (+0.56)%

Market Cap

USD 51.75B

Volume

0.97M

Yahoo Analyst Target

USD 201.83 (18.80%)

STA Analyst Target

USD 200.09 (17.78%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Shire PLC is a biotech company. The Company is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines for patients with rare diseases and other select conditions.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-05-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
AMGN Amgen Inc.

+1.89 (+1.07%)

USD 118.02B
GILD Gilead Sciences Inc.

+0.20 (+0.30%)

USD 88.20B
BIIB Biogen Inc.

+2.02 (+0.73%)

USD 59.02B
CELG Celgene Corporation

+1.92 (+2.57%)

USD 55.53B
VRTX Vertex Pharmaceuticals Incorpo..

+0.06 (+0.04%)

USD 39.82B
REGN Regeneron Pharmaceuticals Inc.

-1.92 (-0.65%)

USD 31.78B
ALXN Alexion Pharmaceuticals Inc.

-0.36 (-0.30%)

USD 26.48B
BMRN BioMarin Pharmaceutical Inc.

-1.75 (-1.96%)

USD 15.48B
GRFS Grifols S.A.

-0.03 (-0.13%)

USD 15.39B
INCY Incyte Corporation

-0.23 (-0.34%)

USD 14.11B

ETFs Containing SHPG

BBH VanEck Vectors Biotech ET.. 6.40 % 0.35 %

+0.43 (+0.37%)

USD 0.42B
FPX First Trust US Equity Opp.. 4.31 % 0.59 %

-0.42 (-0.59%)

USD 1.10B
PBI:CA Purpose Best Ideas Fund 4.24 % 0.79 %

N/A

CAD 0.01B
PBI.B:CA Purpose Best Ideas Fund 4.24 % 0.91 %

N/A

CAD 4.87M
FWDI Madrona International 3.66 % 1.25 %

N/A

USD 0.01B
ALFI ETF Series Solutions Trus.. 3.33 % 0.95 %

N/A

USD 24.95
QQXT First Trust NASDAQ-100 Ex.. 1.96 % 0.60 %

-0.11 (-0.22%)

USD 0.09B
QQQE Direxion NASDAQ-100 Equal.. 1.27 % 0.35 %

-0.12 (-0.27%)

USD 0.16B
QQEW First Trust NASDAQ-100 Eq.. 1.27 % 0.60 %

-0.05 (-0.08%)

USD 0.55B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.52% 63% D 68% D+
Dividend Return 0.58% 33% F 40% F
Total Return 10.10% 63% D 69% D+
Trailing 12 Months  
Capital Gain -9.39% 42% F 26% F
Dividend Return 0.56% 13% F 8% F
Total Return -8.83% 42% F 25% F
Trailing 5 Years  
Capital Gain 75.07% 66% D 60% D-
Dividend Return 4.16% 14% F 13% F
Total Return 79.23% 66% D 58% F
Average Annual (5 Year Horizon)  
Capital Gain 11.51% 54% F 59% F
Dividend Return 11.94% 55% F 57% F
Total Return 0.43% 13% F 10% F
Risk Return Profile  
Volatility (Standard Deviation) 44.88% 58% F 24% F
Risk Adjusted Return 26.61% 60% D- 41% F
Market Capitalization 51.98B 99% A+ 99% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
(Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 112.90 8% F 45% F
Price/Book Ratio 1.43 79% C+ 69% D+
Price / Cash Flow Ratio 2.98 8% F 42% F
Price/Free Cash Flow Ratio 12.04 7% F 42% F
Management Effectiveness  
Return on Equity 12.94% 86% B 77% C+
Return on Invested Capital -22.22% 80% B- 26% F
Return on Assets 6.58% 92% A- 82% B-
Debt to Equity Ratio 58.00% 28% F 44% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

SHPG:NGS-Shire plc

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 169.89

Change

+0.94 (+0.56)%

Market Cap

USD 51.75B

Volume

0.97M

Yahoo Analyst Target

USD 201.83 (18.80%)

STA Analyst Target

USD 200.09 (17.78%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

Values as of: 2018-05-22